Loading...

Michael Grundman

TitleAdjunct Professor
InstitutionUniversity of California San Diego
DepartmentNeurosciences
Address9500 Gilman Drive #0948
La Jolla CA 92093
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, Zago W, Ness DK, Griffith SG, Grundman M, Soto J, Ostrowitzki S, Boess FG, Martin-Facklam M, Quinn JF, Isaacson SH, Omidvar O, Ellenbogen A, Kinney GG. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-a-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 Jun 18. PMID: 29913017.
      View in: PubMed
    2. Lipsmeier F, Taylor KI, Kilchenmann T, Wolf D, Scotland A, Schjodt-Eriksen J, Cheng WY, Fernandez-Garcia I, Siebourg-Polster J, Jin L, Soto J, Verselis L, Boess F, Koller M, Grundman M, Monsch AU, Postuma RB, Ghosh A, Kremer T, Czech C, Gossens C, Lindemann M. Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial. Mov Disord. 2018 Apr 27. PMID: 29701258.
      View in: PubMed
    3. Pontecorvo MJ, Siderowf A, Dubois B, Doraiswamy PM, Frisoni GB, Grundman M, Nobili F, Sadowsky CH, Salloway S, Arora AK, Chevrette A, Deberdt W, Dell'Agnello G, Flitter M, Galante N, Lowrey MJ, Lu M, McGeehan A, Devous MD, Mintun MA. Effectiveness of Florbetapir PET Imaging in Changing Patient Management. Dement Geriatr Cogn Disord. 2017; 44(3-4):129-143. PMID: 28787712.
      View in: PubMed
    4. Schenk DB, Koller M, Ness DK, Griffith SG, Grundman M, Zago W, Soto J, Atiee G, Ostrowitzki S, Kinney GG. First-in-human assessment of PRX002, an anti-a-synuclein monoclonal antibody, in healthy volunteers. Mov Disord. 2017 Feb; 32(2):211-218. PMID: 27886407.
      View in: PubMed
    5. Grundman M, Johnson KA, Lu M, Siderowf A, Dell'Agnello G, Arora AK, Skovronsky DM, Mintun MA, Pontecorvo MJ. Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria. Dement Geriatr Cogn Disord. 2016; 41(1-2):80-92. PMID: 26745445.
      View in: PubMed
    6. Novak G, Fox N, Clegg S, Nielsen C, Einstein S, Lu Y, Tudor IC, Gregg K, Di J, Collins P, Wyman BT, Yuen E, Grundman M, Brashear HR, Liu E. Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease. J Alzheimers Dis. 2016; 49(4):1123-34. PMID: 26639957.
      View in: PubMed
    7. Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR. Amyloid-ß 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology. 2015 Aug 25; 85(8):692-700. PMID: 26208959; PMCID: PMC4553028.
    8. Snyder PJ, Kahle-Wrobleski K, Brannan S, Miller DS, Schindler RJ, DeSanti S, Ryan JM, Morrison G, Grundman M, Chandler J, Caselli RJ, Isaac M, Bain L, Carrillo MC. Assessing cognition and function in Alzheimer's disease clinical trials: do we have the right tools? Alzheimers Dement. 2014 Nov; 10(6):853-60. PMID: 25458309.
      View in: PubMed
    9. Harrison J, Rentz DM, McLaughlin T, Niecko T, Gregg KM, Black RS, Buchanan J, Liu E, Grundman M. Cognition in MCI and Alzheimer's disease: baseline data from a longitudinal study of the NTB. Clin Neuropsychol. 2014; 28(2):252-68. PMID: 24521259.
      View in: PubMed
    10. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23; 370(4):322-33. PMID: 24450891.
      View in: PubMed
    11. Hauber AB, Mohamed AF, Johnson FR, Cook M, Arrighi HM, Zhang J, Grundman M. Understanding the relative importance of preserving functional abilities in Alzheimer's disease in the United States and Germany. Qual Life Res. 2014 Aug; 23(6):1813-21. PMID: 24448684.
      View in: PubMed
    12. Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, Sperling R, Wilcock GK, Fox N, Scheltens P, Touchon J, Hendrix S, Andrieu S, Aisen P. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013 Jul; 9(4):438-44. PMID: 23809364.
      View in: PubMed
    13. Grundman M, Pontecorvo MJ, Salloway SP, Doraiswamy PM, Fleisher AS, Sadowsky CH, Nair AK, Siderowf A, Lu M, Arora AK, Agbulos A, Flitter ML, Krautkramer MJ, Sarsour K, Skovronsky DM, Mintun MA. Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline. Alzheimer Dis Assoc Disord. 2013 Jan-Mar; 27(1):4-15. PMID: 23203162.
      View in: PubMed
    14. Greenberg BD, Carrillo MC, Ryan JM, Gold M, Gallagher K, Grundman M, Berman RM, Ashwood T, Siemers ER. Improving Alzheimer's disease phase II clinical trials. Alzheimers Dement. 2013 Jan; 9(1):39-49. PMID: 23164548.
      View in: PubMed
    15. Raghavan N, Samtani MN, Farnum M, Yang E, Novak G, Grundman M, Narayan V, DiBernardo A. The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials. Alzheimers Dement. 2013 Feb; 9(1 Suppl):S21-31. PMID: 23127469.
      View in: PubMed
    16. Sperling RA, Johnson KA, Doraiswamy PM, Reiman EM, Fleisher AS, Sabbagh MN, Sadowsky CH, Carpenter A, Davis MD, Lu M, Flitter M, Joshi AD, Clark CM, Grundman M, Mintun MA, Skovronsky DM, Pontecorvo MJ. Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging. 2013 Mar; 34(3):822-31. PMID: 22878163.
      View in: PubMed
    17. Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol. 2012 Aug; 69(8):1002-10. PMID: 22473769.
      View in: PubMed
    18. Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, Grundman M, Sabbagh MN, Sadowsky CH, Fleisher AS, Carpenter A, Clark CM, Joshi AD, Mintun MA, Skovronsky DM, Pontecorvo MJ. Amyloid-ß assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology. 2012 Oct 16; 79(16):1636-44. PMID: 22786606.
      View in: PubMed
    19. Cedarbaum JM, Jaros M, Hernandez C, Coley N, Andrieu S, Grundman M, Vellas B. Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials. Alzheimers Dement. 2013 Feb; 9(1 Suppl):S45-55. PMID: 22658286.
      View in: PubMed
    20. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Lieberburg I, Arrighi HM, Morris KA, Lu Y, Liu E, Gregg KM, Brashear HR, Kinney GG, Black R, Grundman M. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012 Mar; 11(3):241-9. PMID: 22305802; PMCID: PMC4063417.
    21. Sperling RA, Jack CR, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 2011 Jul; 7(4):367-85. PMID: 21784348; PMCID: PMC3693547.
    22. Black RS, Sperling RA, Safirstein B, Motter RN, Pallay A, Nichols A, Grundman M. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2010 Apr-Jun; 24(2):198-203. PMID: 20505438; PMCID: PMC3715117.
    23. Khachaturian ZS, Barnes D, Einstein R, Johnson S, Lee V, Roses A, Sager MA, Shankle WR, Snyder PJ, Petersen RC, Schellenberg G, Trojanowski J, Aisen P, Albert MS, Breitner JC, Buckholtz N, Carrillo M, Ferris S, Greenberg BD, Grundman M, Khachaturian AS, Kuller LH, Lopez OL, Maruff P, Mohs RC, Morrison-Bogorad M, Phelps C, Reiman E, Sabbagh M, Sano M, Schneider LS, Siemers E, Tariot P, Touchon J, Vellas B, Bain LJ. Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement. 2010 Mar; 6(2):89-97. PMID: 20298968; PMCID: PMC4298995.
    24. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010 Apr; 9(4):363-72. PMID: 20189881.
      View in: PubMed
    25. Price JL, McKeel DW, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009 Jul; 30(7):1026-36. PMID: 19376612; PMCID: PMC2737680.
    26. Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, Tompkins C, Leibman C, Pomfret M, Grundman M. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res. 2009 Apr; 6(2):144-51. PMID: 19355849; PMCID: PMC2825665.
    27. Khachaturian ZS, Snyder PJ, Doody R, Aisen P, Comer M, Dwyer J, Frank RA, Holzapfel A, Khachaturian AS, Korczyn AD, Roses A, Simpkins JW, Schneider LS, Albert MS, Egge R, Deves A, Ferris S, Greenberg BD, Johnson C, Kukull WA, Poirier J, Schenk D, Thies W, Gauthier S, Gilman S, Bernick C, Cummings JL, Fillit H, Grundman M, Kaye J, Mucke L, Reisberg B, Sano M, Pickeral O, Petersen RC, Mohs RC, Carrillo M, Corey-Bloom JP, Foster NL, Jacobsen S, Lee V, Potter WZ, Sabbagh MN, Salmon D, Trojanowski JQ, Wexler N, Bain LJ. A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement. 2009 Mar; 5(2):85-92. PMID: 19328434; PMCID: PMC3959165.
    28. Ryan JM, Grundman M. Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing. J Alzheimers Dis. 2009; 17(2):243. PMID: 19502708.
      View in: PubMed
    29. Hauber AB, Johnson FR, Fillit H, Mohamed AF, Leibman C, Arrighi HM, Grundman M, Townsend RJ. Older Americans' risk-benefit preferences for modifying the course of Alzheimer disease. Alzheimer Dis Assoc Disord. 2009 Jan-Mar; 23(1):23-32. PMID: 18725862.
      View in: PubMed
    30. Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, Fillit H, Foster N, Greenberg B, Grundman M, Sano M, Simpkins J, Schneider LS, Weiner MW, Galasko D, Hyman B, Kuller L, Schenk D, Snyder S, Thomas RG, Tuszynski MH, Vellas B, Wurtman RJ, Snyder PJ, Frank RA, Albert M, Doody R, Ferris S, Kaye J, Koo E, Morrison-Bogorad M, Reisberg B, Salmon DP, Gilman S, Mohs R, Aisen PS, Breitner JC, Cummings JL, Kawas C, Phelps C, Poirier J, Sabbagh M, Touchon J, Khachaturian AS, Bain LJ. A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement. 2008 May; 4(3):156-63. PMID: 18631960; PMCID: PMC2544623.
    31. Pride M, Seubert P, Grundman M, Hagen M, Eldridge J, Black RS. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener Dis. 2008; 5(3-4):194-6. PMID: 18322388.
      View in: PubMed
    32. Grundman M. A quarter century of advancing treatment for Alzheimer's disease with Leon J. Thal. Alzheimers Dement. 2008 Jan; 4(1 Suppl 1):S51-5. PMID: 18632001.
      View in: PubMed
    33. Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol. 2007 Sep; 64(9):1323-9. PMID: 17846273.
      View in: PubMed
    34. Jack CR, Petersen RC, Grundman M, Jin S, Gamst A, Ward CP, Sencakova D, Doody RS, Thal LJ. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging. 2008 Sep; 29(9):1285-95. PMID: 17452062; PMCID: PMC2768818.
    35. DeCarli C, Frisoni GB, Clark CM, Harvey D, Grundman M, Petersen RC, Thal LJ, Jin S, Jack CR, Scheltens P. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol. 2007 Jan; 64(1):108-15. PMID: 17210817.
      View in: PubMed
    36. Grundman M, Petersen RC, Bennett DA, Feldman HH, Salloway S, Visser PJ, Thal LJ, Schenk D, Khachaturian Z, Thies W. Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: what have we learned? Alzheimers Dement. 2006 Jul; 2(3):220-33. PMID: 19595891.
      View in: PubMed
    37. Fleisher A, Grundman M, Jack CR, Petersen RC, Taylor C, Kim HT, Schiller DH, Bagwell V, Sencakova D, Weiner MF, DeCarli C, DeKosky ST, van Dyck CH, Thal LJ. Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol. 2005 Jun; 62(6):953-7. PMID: 15956166.
      View in: PubMed
    38. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005 Jun 09; 352(23):2379-88. PMID: 15829527.
      View in: PubMed
    39. Schenk DB, Seubert P, Grundman M, Black R. A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease. Neurodegener Dis. 2005; 2(5):255-60. PMID: 16909006.
      View in: PubMed
    40. Grundman M. Weight loss in the elderly may be a sign of impending dementia. Arch Neurol. 2005 Jan; 62(1):20-2. PMID: 15642845.
      View in: PubMed
    41. Karajeh MA, Hadjivassiliou M, Hurlstone P, Grundman MJ. Neurological sequelae of Crohn's disease: opportunity to study common etiological pathways. J Gastroenterol Hepatol. 2004 Sep; 19(9):1093-4. PMID: 15304135.
      View in: PubMed
    42. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004 Jan; 61(1):59-66. PMID: 14732621.
      View in: PubMed
    43. Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, Thomas R, Thal LJ. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep. 2003 Nov 01; 26(7):893-901. PMID: 14655926; PMCID: PMC4418658.
    44. Ji M, Xiong C, Grundman M. Hypothesis testing of a change point during cognitive decline among Alzheimer's disease patients. J Alzheimers Dis. 2003 Oct; 5(5):375-82. PMID: 14646028.
      View in: PubMed
    45. Grundman M, Capparelli E, Kim HT, Morris JC, Farlow M, Rubin EH, Heidebrink J, Hake A, Ho G, Schultz AN, Schafer K, Houston W, Thomas R, Thal LJ. A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients. Life Sci. 2003 Jun 20; 73(5):539-53. PMID: 12770610.
      View in: PubMed
    46. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003 Jun 04; 289(21):2819-26. PMID: 12783912.
      View in: PubMed
    47. Aisen PS, Schafer K, Grundman M, Thomas R, Thal LJ. NSAIDs and hypertension. Arch Intern Med. 2003 May 12; 163(9):1115; author reply 1115-6. PMID: 12742818.
      View in: PubMed
    48. Thal LJ, Thomas RG, Mulnard R, Sano M, Grundman M, Schneider L. Estrogen levels do not correlate with improvement in cognition. Arch Neurol. 2003 Feb; 60(2):209-12. PMID: 12580705.
      View in: PubMed
    49. Grundman M, Jack CR, Petersen RC, Kim HT, Taylor C, Datvian M, Weiner MF, DeCarli C, DeKosky ST, van Dyck C, Darvesh S, Yaffe K, Kaye J, Ferris SH, Thomas RG, Thal LJ. Hippocampal volume is associated with memory but not monmemory cognitive performance in patients with mild cognitive impairment. J Mol Neurosci. 2003; 20(3):241-8. PMID: 14501003.
      View in: PubMed
    50. Pasquier F, Fukui T, Sarazin M, Pijnenburg Y, Diehl J, Grundman M, Miller BL. Laboratory investigations and treatment in frontotemporal dementia. Ann Neurol. 2003; 54 Suppl 5:S32-5. PMID: 12833367.
      View in: PubMed
    51. Grundman M, Sencakova D, Jack CR, Petersen RC, Kim HT, Schultz A, Weiner MF, DeCarli C, DeKosky ST, van Dyck C, Thomas RG, Thal LJ. Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. J Mol Neurosci. 2002 Aug-Oct; 19(1-2):23-7. PMID: 12212787.
      View in: PubMed
    52. Grundman M, Farlow M, Peavy G, Kim HT, Capparelli E, Schultz AN, Salmon DP, Ferris SH, Mobs R, Thomas RG, Schafer K, Campbell K, Hake AM, Schoos B, Thal LJ. A phase I study of AIT-082 in healthy elderly volunteers. J Mol Neurosci. 2002 Jun; 18(3):283-93. PMID: 12059047.
      View in: PubMed
    53. Grundman M, Grundman M, Delaney P. Antioxidant strategies for Alzheimer's disease. Proc Nutr Soc. 2002 May; 61(2):191-202. PMID: 12133201.
      View in: PubMed
    54. Grundman M. Vitamin E and Alzheimer disease: the basis for additional clinical trials. Am J Clin Nutr. 2000 Feb; 71(2):630S-636S. PMID: 10681271.
      View in: PubMed